GSTM1 and chronic kidney disease: In the fully adjusted model (Model II:adjusted for sex, ethnicity, age, BMI, Hb, Scr, APACHE-IV score, ARF, AF, ACS, CHF, CKD, COPD, diabetes mellitus, GB, hypertension, sepsis, anti-platelet, anticoagulant, glucocorticoid, carbapenems, cephalosporins, vancomycin, and mechanical ventilation), an increase in platelet count of 10 × 109/L is associated with a 2.5% decrease in mortality (OR = 0.975, 95% CI: 0.966–0.984, p < 0.0001).